206 related articles for article (PubMed ID: 16197363)
1. Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety.
Gates BJ; Nguyen TT; Setter SM; Davies NM
Expert Opin Pharmacother; 2005 Oct; 6(12):2117-40. PubMed ID: 16197363
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of meloxicam. A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug.
Davies NM; Skjodt NM
Clin Pharmacokinet; 1999 Feb; 36(2):115-26. PubMed ID: 10092958
[TBL] [Abstract][Full Text] [Related]
3. Review of clinical trials and benefit/risk ratio of meloxicam.
Barner A
Scand J Rheumatol Suppl; 1996; 102():29-37. PubMed ID: 8628979
[TBL] [Abstract][Full Text] [Related]
4. Meloxicam.
Fleischmann R; Iqbal I; Slobodin G
Expert Opin Pharmacother; 2002 Oct; 3(10):1501-12. PubMed ID: 12387696
[TBL] [Abstract][Full Text] [Related]
5. [Meloxicam].
Sternon J; Appelboom T
Rev Med Brux; 1998 Feb; 19(1):29-32. PubMed ID: 9553452
[TBL] [Abstract][Full Text] [Related]
6. Meloxicam in rheumatoid arthritis.
Ahmed M; Khanna D; Furst DE
Expert Opin Drug Metab Toxicol; 2005 Dec; 1(4):739-51. PubMed ID: 16863437
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.
Hawkey C; Kahan A; Steinbrück K; Alegre C; Baumelou E; Bégaud B; Dequeker J; Isomäki H; Littlejohn G; Mau J; Papazoglou S
Br J Rheumatol; 1998 Sep; 37(9):937-45. PubMed ID: 9783757
[TBL] [Abstract][Full Text] [Related]
8. A review of the clinical pharmacokinetics of meloxicam.
Türck D; Roth W; Busch U
Br J Rheumatol; 1996 Apr; 35 Suppl 1():13-6. PubMed ID: 8630630
[TBL] [Abstract][Full Text] [Related]
9. High response rate in the phase I/II study of meloxicam in juvenile rheumatoid arthritis.
Foeldvari I; Burgos-Vargas R; Thon A; Tuerck D
J Rheumatol; 2002 May; 29(5):1079-83. PubMed ID: 12022326
[TBL] [Abstract][Full Text] [Related]
10. Safety of meloxicam: a global analysis of clinical trials.
Distel M; Mueller C; Bluhmki E; Fries J
Br J Rheumatol; 1996 Apr; 35 Suppl 1():68-77. PubMed ID: 8630641
[TBL] [Abstract][Full Text] [Related]
11. Channelling of patients taking NSAIDs or cyclooxygenase-2-specific inhibitors and its effect on interpretation of outcomes.
MacDonald TM; Pettitt D; Lee FH; Schwartz JS
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii3-10. PubMed ID: 14585912
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and safety of single and multiple oral doses of meloxicam in adult horses.
Noble G; Edwards S; Lievaart J; Pippia J; Boston R; Raidal SL
J Vet Intern Med; 2012; 26(5):1192-201. PubMed ID: 22860573
[TBL] [Abstract][Full Text] [Related]
13. A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis.
Huskisson EC; Ghozlan R; Kurthen R; Degner FL; Bluhmki E
Br J Rheumatol; 1996 Apr; 35 Suppl 1():29-34. PubMed ID: 8630633
[TBL] [Abstract][Full Text] [Related]
14. Meloxicam.
Noble S; Balfour JA
Drugs; 1996 Mar; 51(3):424-30; discussion 431-32. PubMed ID: 8882380
[TBL] [Abstract][Full Text] [Related]
15. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis.
Dequeker J; Hawkey C; Kahan A; Steinbrück K; Alegre C; Baumelou E; Bégaud B; Isomäki H; Littlejohn G; Mau J; Papazoglou S
Br J Rheumatol; 1998 Sep; 37(9):946-51. PubMed ID: 9783758
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
Layton D; Hughes K; Harris S; Shakir SA
Rheumatology (Oxford); 2003 Nov; 42(11):1332-41. PubMed ID: 12810929
[TBL] [Abstract][Full Text] [Related]
17. Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetic dependent.
Harirforoosh S; Aghazadeh-Habashi A; Jamali F
Clin Exp Pharmacol Physiol; 2006 Oct; 33(10):917-24. PubMed ID: 17002668
[TBL] [Abstract][Full Text] [Related]
18. Safety of selective cyclooxygenase-2 inhibitors and a basic non-steroidal anti-inflammatory drug (NSAID) in Japanese patients with NSAID-induced urticaria and/or angioedema: Comparison of meloxicam, etodolac and tiaramide.
Inomata N; Osuna H; Yamaguchi J; Onoda M; Takeshita Y; Chiba Y; Kambara T; Ikezawa Z
J Dermatol; 2007 Mar; 34(3):172-7. PubMed ID: 17291297
[TBL] [Abstract][Full Text] [Related]
19. [Meloxicam (Mobic): a review of its pharmacological and clinical profile].
Ogino K; Saito K; Osugi T; Satoh H
Nihon Yakurigaku Zasshi; 2002 Dec; 120(6):391-7. PubMed ID: 12528470
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials.
Schoenfeld P
Am J Med; 1999 Dec; 107(6A):48S-54S. PubMed ID: 10628593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
